Previous 10 | Next 10 |
2024-04-03 17:24:42 ET Gainers: Signature Bank ( OTC:SBNY ) +10% . MacroGenics ( MGNX ) +9% . Simulations Plus ( SLP ) +7% . Annexon ( ANNX ) +6% . 2seventy ( TSVT ) +5% . Losers: Cadiz ( CDZIP ) -11% . ...
2024-04-03 09:34:51 ET Summary 2seventy bio is focusing on ABECMA, their CAR-T cell therapy for multiple myeloma, and expects label expansion approval. ABECMA has shown positive real-world evidence and has the potential for significant market growth. The company's financial po...
- Company Now Exclusively Focused on Development and Commercialization of Abecma - 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has ac...
2024-03-20 17:53:04 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb Is Not A Buy For Me Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Pa...
2024-03-20 17:19:13 ET More on 2seventy bio 2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript 2seventy bio: An Overload Of Troubles At This Small Pharma Bristol Myers wins FDA AdCom backing for Abecma label expansion Bristol Myers, 2seventy bio to fa...
2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company’s Board of Directors (the “Boar...
2024-03-19 17:37:35 ET Gainers: Taysha Gene Therapies ( TSHA ) +32% . Canopy Growth Corporation ( CGC ) +14% . Sarcos Technology and Robotics ( STRC ) +12% . Adicet ( ACET ) +6% . Bridger Aerospace Group Holdings ( BAER ) +4%...
2024-03-18 07:44:53 ET More on premarket gainers & stock. Tilray: Big Opportunities Ahead In Germany And Alcohol Segment Aurora Cannabis: Barely Surviving Or Soon To Be Thriving? Canopy Growth Corporation (CGC) Q3 2024 Earnings Call Transcript Tilray wins...
2024-03-16 07:58:13 ET More on Bristol-Myers, 2seventy bio, etc. Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conf...
The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and received a positive CHMP Opinion by the European Medicines Agency based on KarMMa-3 Bristol Myers Squibb (N...
News, Short Squeeze, Breakout and More Instantly...
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired th...
2024-06-06 06:15:03 ET Goldman Sachs analyst issues SELL recommendation for TSVT on June 6, 2024 05:06AM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.56 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media pa...